Table 1 Patient and treatment characteristics
Characteristic | Total(n = 28) n (%) | Monotherapy(n = 12) n (%) | Combination therapy(n = 16) n (%) | P |
|---|---|---|---|---|
Age (years, median) | 54 (36–79) | 52 (36–79) | 57 (43–64) | |
Sex | ||||
Female | 12 (42.9) | 5 (41.7) | 7 (43.8) | 0.912 |
Male | 16 (57.1) | 7 (58.3) | 9 (56.2) | |
ECOG | ||||
0–1 | 22 (78.6) | 10 (83.3) | 12 (75.0) | 0.595 |
2 | 6 (21.4) | 2 (16.7) | 4 (25.0) | |
Primary tumor site | ||||
GBC | 9 (32.1) | 3 (25.0) | 6 (37.5) | 0.483 |
CCA | 19 (67.9) | 9 (75.0) | 10 (62.5) | |
Metastatic site | ||||
Intra-abdominal lymph node | 16 (57.1) | 6 (50.0) | 10 (62.5) | |
Liver | 14 (50.0) | 2 (16.7) | 12 (75.0) | 0.086 |
Peritoneum | 8 (28.6) | 3 (25.0) | 5 (31.3) | |
Lung | 8 (28.6) | 6 (50.0) | 2 (12.5) | |
Others | 16 (57.1) | 7 (58.3) | 9 (56.3) | |
Number of metastatic sites | ||||
1–2 | 13 (46.4) | 5 (41.7) | 8 (50.0) | 0.662 |
≥ 3 Treatment line | 15 (53.6) | 7 (58.3) | 8 (50.0) | |
2 | 11 (39.3) | 5 (41.7) | 6 (37.5) | 0.823 |
3–4 | 17 (60.7) | 7 (58.3) | 10 (62.5) | |